Sun Pharmaceutical (SUNPHARMA) — concall transcript

📢 Key Event
Sun Pharma reports Q2 FY25 revenue of ₹13,264 crores, up 10.5% YoY, with EBITDA margin at 29.6%, driven by 20.3% US sales growth and 19.2% specialty sales growth.

🔄 What Changed
Revenue growth accelerated to 10.5% YoY from prior periods, and global specialty sales grew 19.2% YoY, indicating stronger performance in high-margin segments.

🔮 What's Next
R&D spend targeted at 7-8% of revenue for FY25; potential Leqselvi launch within weeks if court judgment is favorable; ILUMYA expansion into psoriatic arthritis pending regulatory approval.

💡 Investor Takeaway
Sun Pharma is gaining momentum in high-growth markets and specialty segments, but R&D investment may pressure near-term margins despite strong top-line growth.

Sun Pharmaceutical reported Q2 FY25 revenue of ₹13,264 crores up 10.5% YoY with EBITDA margin at 29.6%, driven by strong US sales growth of 20.3% and global specialty sales rising 19.2%. The company highlighted progress on key launches including Leqselvi and ILUMYA for psoriatic arthritis, with potential market entry within weeks if litigation resolves favorably. R&D spend is targeted at 7-8% of revenue for FY25, down from prior range due to study delays, while emerging markets like Brazil and Mexico focus on top-line growth over profitability. Management emphasized cautious expansion in specialty segments and strategic M&A in oncology and dermatology.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUNPHARMA ✨ Ask AI About This

About Sun Pharmaceutical Industries Ltd (SUNPHARMA)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹4,63,791.45 Cr P/E: 38.4 ROE: 14.6% ROCE: 18.7% Div Yield: 0.83%

View full SUNPHARMA stock details →

📡 Get AI alerts when SUNPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUNPHARMA — Free

💡 Ask AI about this filing

"How will R&D spend impact profitability in H2 FY25?" "What is the expected timeline for ILUMYA's psoriatic arthritis launch?" "How does Sun Pharma plan to monetize its emerging market growth?"

Ask AI Free →

📊 More SUNPHARMA filings

See all SUNPHARMA filings →

🔥 Also filed on 30 September 2024

BAJFINANCE Bajaj Finance Ltd concall transcript M&M Mahindra & Mahindra Ltd concall transcript SBIN State Bank of India concall transcript ULTRACEMCO UltraTech Cement Ltd concall transcript TITAN Titan Company Ltd concall transcript ETERNAL Eternal Ltd concall transcript

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUNPHARMA files new disclosures

Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SUNPHARMA — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd